Inducible nitric oxide synthase (iNOS) is active as a homodimer. a cell-based assay suitable for high-throughput screening (hTS) was generated to identify inhibitors of iNOS dimerization using the InteraX enzyme complementation technology of applied Biosystems. The cells contain 2 chimeric proteins of complementing deletion mutants of β-galactosidase, each fused to the oxygenase domain of human iNOS. The assay was characterized using known iNOS dimerization inhibitors, which gave a decrease in β-galactosidase activity. Surprisingly, the assay was also able to identify compounds that have the same profile as known inhibitors of fully formed dimeric iNOS by causing an increase in β-galactosidase activity. The iNOS InteraX assay was used to screen ~800,000 compounds in a 384-well format. after hit confirmation, 3359 compounds were taken forward for full IC 50 determination in InteraX and cytotoxicity assays. Of these compounds 40.5% were confirmed as greater than 10-fold more active in InteraX compared to a cytotoxicity assay and were classified as potential iNOS dimerization inhibitors as they did not inhibit β-galactosidase alone. In the same primary screen, 901 compounds gave a significant increase in β-galactosidase activity. many of these were known inhibitors of iNOS. after IC 50 determination in InteraX and cytotoxicity assays, 182 novel compounds remained as potential arginine-competitive inhibitors of dimeric
INTRODUCTION
i NDUCIBLE NOS IS a hOmODImErIC, CaLmODULIN-BINDINg ENzymE that generates nitric oxide (NO) from arginine and molecular oxygen and has been implicated in a wide variety of diseases. There is therefore an ongoing search to try and identify iNOS inhibitors that may be useful for treating inflammatory diseases. a number of iNOS selective inhibitors have been identified that may have high affinity for the enzyme. 1,2 however, these compounds are often competitive with arginine, and the high concentrations (100 µm) found in the cell typically result in a 50-to 100-fold difference between the potency of enzyme inhibition and the blockade of iNOS activity in intact cells.
Using cell-based iNOS induction high-throughput screening (hTS) assays, other compounds have been identified that bind to iNOS during synthesis, [3] [4] [5] and evidence suggests that these act to prevent correct folding and dimerization. 6 These compounds do not compete with intracellular arginine, and so affinity for the iNOS monomer typically matches the potency observed in cells. Cellular assays that measure inhibition of NO production can also identify compounds that do not bind iNOS but rather are inhibitors of iNOS expression. 2 In one example, calmodulindependent protein kinase inhibitors were identified by an hTS approach. 7 Therefore, it is desirable to use an iNOS-specific cell assay to generate new inhibitors that are highly active against cellular iNOS.
To this end, a cell-based assay was configured to identify iNOS dimerization inhibitors using the InteraX system from applied Biosystems. This technology [8] [9] [10] uses β-galactosidase enzyme complementation to generate a detectable signal. The protein partners of interest (in this case, iNOS oxygenase domains) are coexpressed as individual fusions with separate reporter enzyme β-galactosidase mutants. The individual reporter enzyme mutants are in themselves enzymatically inactive, but when brought into close proximity by their protein fusion partners, β-galactosidase activity is generated. The level of β-galactosidase mutant complementation is proportional to the degree of proteinprotein interaction. Interestingly, the iNOS InteraX hTS assay as described here could not only identify inhibitors of iNOS dimerization but was also used to identify compounds that appeared to promote dimerization of iNOS monomers.
MATERIALS AND METHODS

Materials
Black 384-well plates were purchased from greiner Bio-one (Stonehouse, UK).
heat-inactivated fetal bovine serum (FBS) was obtained from Sigma-aldrich (Dorset, UK). Streptomycin, penicillin, geneticin, hygromycin B, L-glutamine, sodium pyruvate, Dulbecco's modified Eagle's medium (DmEm), phenol red-free DmEm and rPmI 1640 were purchased from Invitrogen (Paisley, UK). gal-Screen  reagent was obtained from applied Biosystems (Foster City, Ca); cell culture flasks were obtained from Fisher Scientific (Loughborough, UK); oligonucleotides were obtained from Eurogentec (Southampton, UK). all other chemicals were purchased from Sigma-aldrich and were of the highest purity available. iNOS inhibitors ( Fig. 1a) were synthesized in the Department of medicinal Chemistry, astrazeneca r&D Charnwood (Loughborough, UK). Compound 1 was previously described, 3 compound 2 is structurally related to Fr260330 4 and described in WO-09827108, compound 3 was previously described as ar-C102222, 11 and compound 4 is described in WO-00178719.
Cloning
The InteraX system vectors (pIX3, pIX6, pIX9, pIX12) were obtained from applied Biosystems. a cDNa encoding human iNOS oxygenase domain residues 82-508 was used as a template for PCr. Two separate products were amplified using PaC1kozak (5′-gCgCTTaaTTaaCaCCaTgCCaCggCaT gTgag) as the 5′ primer and mFEopen (5′-aTaTCaaTTggg gTCTCCgCTTCTCgTC) and mFEstop (5′-aTaTCaaTTgCT agggTCTCCgCTTCTCgT), respectively, as the 3′ primers. The PCr product generated using PaC1kozak and mFEstop was cloned into the PacI and mfeI sites of both pIX6 and pIX12 using standard molecular biology methods 12 to generate pIX6-iNOS and pIX12-iNOS-each capable of expressing ∆αβ-galactosidase-iNOS fusion protein and ∆ωβ-galactosidase-iNOS fusion protein, respectively. Likewise, the PCr product without a stop codon, generated using PaC1kozak and mFEopen, was cloned into the PacI and mfeI sites of both pIX3 and pIX9 to give pIX3-iNOS and pIX9-iNOS, respectively, each capable of expressing iNOS-∆αβ-galactosidase fusion protein and iNOS-∆ωβ-galactosidase, respectively. The sequences of all clones were checked using standard di-deoxy terminator sequencing.
Cell culture
The mouse myofibroblast C2C12 and hEK-293T cell lines were obtained from ECaCC (Salisbury, UK) and cultured in DmEm, containing 5% FBS and 4 mm L-glutamine. Cells were incubated at 37 °C with 5% CO 2 , 95% humidity.
replication-deficient retroviruses (rDrs) were generated using the 4 pIX-iNOS plasmids and each pIX vector, without an insert, as controls. Separate flasks of hEK-293T cells were transfected with a pIX vector plus the retrovirus helper plasmid pCL-ECO (Stratagene, La Jolla, Ca) using Fugene 6 (roche, Burgess hill, UK). after a 24-h incubation, the supernatants from each vector transfection were harvested separately and filtered to remove hEK-293T cell contamination.
Transductions of subconfluent C2C12 cells were performed in the presence of 8 µg/mL polybrene by addition of 2 supernatants containing 2 individual rDrs. after a 24-h incubation at 37 °C, the media from each separate transduction were removed and replaced with fresh media containing 0.75 mg/mL geneticin and 0.5 mg/mL hygromycin B. Selection of transduced cells was continued for a further 72 h before transferring the surviving cells into fresh media containing 0.5 mg/mL geneticin and 0.25 mg/mL hygromycin B. Five days later, the cells were passaged into fresh media containing 0.2 mg/mL geneticin and 0.15 mg/ mL hygromycin B and routinely cultured at these concentrations of antibiotics from this point. after testing mixed populations in the InteraX assay, individual clonal cell lines of active populations were generated by dilution cloning using standard methods.
Cellular iNOS inhibition assay
The human colorectal carcinoma cell line DLD-1 was routinely cultured in rPmI 1640 supplemented with 10% (v/v) FBS and 2 mm L-glutamine at 37 °C in 5% CO 2 . Cells were plated at a density of 0.5 × 10 6 per cm 2 in culture media in 24-well plates and were incubated overnight at 37 °C/5% CO 2 to allow them to settle and adhere. The following day, the media were aspirated and replaced with assay buffer (rPmI 1640 media containing a final concentration of 100 µm arginine and 10% FBS). after a 6-h incubation at 37 °C, the media were removed and cells induced by adding assay buffer containing recombinant human γ-IFN (1000 U/mL), TNF-α (200 U/mL), IL-6 (200 U/mL), and IL-1β (250 U/mL). after an 18-h incubation at 37 °C, the media were removed and the cells washed once with phosphate-buffered saline (PBS). Immediately, 0.15 mL of assay buffer containing 100 µm verapamil (an inhibitor of P-glycoprotein) and diluted inhibitor were added to each well. The plates were incubated for 5 h at 37 °C/5% CO 2 to allow nitrite, a stable breakdown product of NO, to accumulate. The concentration of nitrite in the media was then determined by the griess assay. 13
Cellular iNOS induction inhibition assay
an assay measuring the functional inhibition of iNOS during induction was performed using DLD-1 cells in a similar manner. Cells were plated in assay plates as above and incubated at 37 °C/5% CO 2 to allow the cells to adhere. The following day, the media were aspirated and replaced with assay buffer containing diluted inhibitor. after a 1-h incubation at 37 °C, an equal volume of assay buffer containing recombinant cytokines (as above) was added to each well and the plates incubated at 37 °C for 18 h, after which nitrite levels in the media were measured using the griess assay.
Compound screening
Test compounds at known concentrations were formatted 320 per plate in matrix polypropylene 384 plates (Fisher Scientific), with each well containing 1 µL of a single compound in 100% DmSO. Compounds were diluted with 40 µL 1% DmSO, and 2.5 µL of each diluted compound was transferred into 6 assay plates using a 384-well dispenser. C2C12 cells stably expressing iNOS-β-galactosidase proteins were diluted in media to a density of 4 × 10 5 cells per mL, and 25 µL per well was dispensed on top of the compounds. Compound 2, at a final concentration of 10 µm, was used as the positive control test compound. after incubation at 37 °C for 24 h, the β-galactosidase activity in each well was detected using the gal-Screen  reagent. This detection mix was generated by mixing 1 part substrate reagent with 25 parts of solution a and allowed to equilibrate to ambient temperature in the dark, and then 25 µL of the mix was added to all wells of the plate. Plates were incubated for 18 min at room temperature, and luminescence in each well was measured using a hamamatsu FDSS6000 reader in luminescent mode, reading each plate for 5 s and for a total of 8 readings. These conditions were also used to carry out full IC 50 curves on compounds that caused β-galactosidase inhibition in the assay. however, for compounds that caused an increase in β-galactosidase activity, the incubation time of the assay was reduced to 5 min to maintain assay linearity.
Resazurin cytoxicity assay
assay plates containing compounds and C2C12 cells were generated and incubated for 24 h in the same manner as for the InteraX assay. In this case, staurosporine at a final concentration of 10 µm was used as a positive control. To each well of the assay plate, 2.5 µL of resazurin Tox 4-1 (Sigma-aldrich) was added and incubated for 2 h at 37 °C/5% CO 2 to allow the reduction of resazurin from blue to pink. The plates were then read using an Envision 2101 multilable reader (PerkinElmer, Waltham, ma), detecting from the top of the well, using excitation λ ex 560 nm and emission λ em 590 nm with a 50:50 mirror.
β-galactosidase assay
To identify inhibitors of β-galactosidase, we generated a 384well plate assay using recombinant β-galactosidase (Sigmaaldrich). Initially, 2.5 µL of diluted compounds in 1% DmSO was added to the wells of a 384-well plate. β-galactosidase was diluted to a final concentration of 0.001 U/mL in DmEm containing 0.1% bovine serum albumin (BSa), and 25 µL of the diluted enzyme was added to each well. The plates were incubated for 1 h at room temperature and β-galactosidase activity determined using the gal-Screen  reagent as above. after a 5-min incubation at room temperature, luminescence was measured on the FDSS6000.
Data analysis
z′ determination 14 was used to assess the quality of the assays and reflects the variation of data and the dynamic range of an assay signal.
The calculation of the percentage inhibition values for the compounds tested was carried out using the following equation:
where Cr = control reading (cells, assay mix, and compound solvent), Sr = sample reading (cells, assay mix, and test compound), and Br = background reading (assay mix and compound solvent).
RESULTS
Characterization of known iNOS inhibitors
Compound 1 and a close analog of compound 2 have previously been identified as iNOS dimerization inhibitors 3, 4 and bind to iNOS monomers to prevent the formation of active iNOS dimers. In contrast, compound 3 (ar-C102222) and compound 4 inhibit fully formed dimeric iNOS 1, 2 and are known to compete with arginine in the active site of dimeric iNOS. To confirm the different mechanisms of inhibition, we tested the compounds in 2 cell-based iNOS assays that use endogenous iNOS.
In the first of these assays, the cellular iNOS inhibition assay, the iNOS enzyme was induced in DLD-1 cells using a cytokine cocktail, and after an 18-h incubation, fresh media containing diluted compounds were added to the cells and the inhibition of NO production by iNOS measured after a 5-h incubation. In this assay format, compound 1 showed very weak iNOS inhibition, having an IC 50 of only 17 µm (Fig. 1b) . Similarly, compound 2 was inactive in this assay at 10 µm. In contrast, compounds 3 and 4 showed an IC 50 of 1 µm and 0.34 µm, respectively.
In the second assay, the cellular iNOS induction inhibition assay, the cells were equilibrated with inhibitor before inducing iNOS expression with a cytokine cocktail. When compounds 1 and 2 were tested in this induction assay, they showed a remarkable improvement in potency compared to the cellular iNOS inhibition assay, whereas compound 3 only showed a slight improvement in potency ( Fig. 1b) . These data suggest that compounds 1 and 2 are only active when iNOS is being translated, probably acting as potent inhibitors of iNOS assembly and dimerization.
Identifying the correct configuration of iNOS relative to β-galactosidase
The sequence of the human iNOS oxygenase domain, residues 82 to 508, 15 was used as the starting point to generate the pIX-iNOS vectors. The murine C2C12 cell line was transduced with rDrs to generate separate cell populations expressing each combination of iNOS-β-galactosidase and β-galactosidase-iNOS fusion proteins. Each cell population was plated out at 10,000 cells per well and incubated for 24 h to allow the cells to express the iNOS-β-galactosidase chimeric proteins. The known dimerization inhibitor, compound 1, was added at 10 µm as a control. Figure 2 shows that 2 combinations of pIX-iNOS vectors (pIX6-iNOS with pIX9-iNOS and pIX3-iNOS with pIX12-iNOS) gave enhanced levels of β-galactosidase activity, which were inhibited to background levels of β-galactosidase activity in the presence of 10 µm compound 1. In a separate experiment, 10 µm of the structurally different inhibitor, compound 2, also fully inhibited the β-galactosidase activity of the C2C12 cells transduced with the pIX6-iNOS/pIX9-iNOS and pIX3-iNOS/pIX12-iNOS combinations, respectively (data not shown). Figure 2b is a model to explain the β-galactosidase activity seen with different combinations of iNOS-β-galactosidase and β-galactosidase-iNOS fusion proteins. Several clonal cell lines expressing the combination of pIX6-iNOS and pIX9-iNOS chimeric proteins were then isolated by dilution cloning, and the one that gave the highest signal-to-background ratio after 24 h was used in all further experiments.
Properties of compounds in the InteraX assay
Using the pIX6-iNOS/pIX9-iNOS clonal cell line, the concentration-dependent inhibition of β-galactosidase enzyme activity by compounds 1 and 2 was measured in a 384-well format (Fig. 3a) . The average IC 50 for these compounds over 3 experiments was 0.63 nm and 31 nm, respectively (Fig. 1b) . The rank order of potency of the 2 dimerization inhibitors is similar to those determined in the cellular iNOS induction assay, although both compounds are more potent (7-and 6-fold, respectively) in the InteraX assay compared to the iNOS induction inhibition assay.
In contrast to these data, when compounds 3 and 4 were tested in the InteraX assay, they gave a dramatic increase in β-galactosidase activity (Fig. 3b) rather than inhibition.
Western blotting experiments demonstrated that the decreased β-galactosidase activity in the cells caused by compounds 1 and 2 and the increased β-galactosidase activity caused by compounds 3 and 4 were not due to changes in total β-galactosidase protein production, but the levels of protein remained identical to controls (data not shown). Compounds 3 and 4 are known to compete with arginine in the active site of dimeric iNOS. 2 arginine promotes iNOS monomer dimerization and stabilization of iNOS dimers, 3, 16, 17 so it is possible that these compounds behave similarly to arginine.
To investigate further the mechanism of action of the different types of compounds in the InteraX assay, we generated concentration-response curves of compound 3 in the presence of fixed concentrations of compound 2 (Fig. 4a ) and vice versa (Fig.  4b) . as can be seen in Figure 4a , compound 2 shows inhibition of the increase in β-galactosidase activity in the InteraX assay caused by compound 3. Schild analysis of this inhibition demonstrates (Fig. 4a inset) that compound 2 acts as a competitive inhibitor of the effect of compound 3 with a pa 2 of 7 (100 nm). In a similar manner, compound 3 prevents the inhibition of compound 2 (Fig. 4b) and appears to be acting competitively with a pa 2 of 6.4 (~400 nm). The pa 2 of compounds 2 and 3 corresponds well with their IC 50 s in the whole-cell iNOS induction inhibition assay of 180 nm and 250 nm, respectively (Fig. 1b) .
Screening results
after optimizing the assay protocol, a high-throughput screen was carried out on approximately 800,000 compounds.
The assay gave a robust signal-to-background ratio with the average over the whole screen of 10-fold and an average z′ factor of 0.659. On the occasional plate where the z′ value slipped below 0.5, the plate was repeated.
The frequency distribution of primary screen data is shown in Figure 5a . The hTS identified compounds that inhibited the β-galactosidase activity in the assay and are described as potential dimerization inhibitors (to the right of the distribution). Compounds were also identified that appeared to enhance the β-galactosidase activity of the cells (to the left of the distribution), and these were potentially compounds that could compete with arginine and stabilize iNOS dimers. inset shows the different time points needed to measure β-galactosidase activity for activators and inhibitors in the InteraX assay using the FDSS6000. as the β-galactosidase activity was greater for the "enhancer" compounds, to prevent the increased luminescence from saturating the CCD camera in the reader, we used a shorter time period to read the wells than for the "inhibitor" compounds. Figure 5b describes the percentage of the total number of compounds that were on each side of the distribution. The percentage inhibition cutoff for compounds that were apparent dimerization inhibitors progressing into the retest stage was >22%. at this stage, duplicated compounds in the output were removed. The total number of compounds taken forward for retesting was 12,175. These compounds were then tested again in triplicate against the InteraX assay and in a single-point test in the cytotoxicity assay, and the results are shown in Figure 6 . The 3 selection criteria for taking compounds for further testing were all compounds that were <10% active in the cytotoxicity assay (irregardless of InteraX inhibition), plus compounds that showed >90% inhibition in the triplicate InteraX assay (irregardless of percentage toxicity), plus compounds that had >50% inhibition in InteraX and also had a >40% difference in activity in InteraX compared to the cytotoxicity assay. The 3359 compounds selected for further Compounds that gave >20% inhibition of β-galactosidase activity were potential iNOS dimerization inhibitors, and compounds that gave an increase in β-galactosidase activity (and hence a negative reading in percent inhibition) were compounds that may promote the formation of iNOS dimers. Inset: Example time course of β-galactosidase luminescence in the assay in the presence of DmSO (▲), 10 µm compound 2 (▼), and 10 µm compound 3 (■). (b) testing are denoted in the boxed area in Figure 6 . These went forward for 10-point IC 50 determination in the InteraX and resazurin cytotoxicity assays. The number of compounds at specified cytotoxicity/InteraX ratios from these assays is shown in Figure 7 .
Dimerization inhibitor screening cascade
It was not surprising that the majority of compounds active in the InteraX inhibition assay also showed activity in the cytotoxicity assay, as any compound toxicity would result in a reduction in β-galactosidase activity. however, a significant number of the 3359 compounds (40.4%) showed >10-fold higher potency in the InteraX assay compared to the cytotoxicity assay. It was possible that these compounds were simply inhibitors of β-galactosidase, but evaluation using recombinant β-galactosidase in an enzyme assay showed that this was not the case. These compounds were therefore selected as potential iNOS dimerization inhibitors.
Dimer stabilizers (InteraX activators)
The percentage cutoff for selecting compounds from the InteraX hTS that behaved as potential iNOS dimerization promoters or dimer stabilizers was -30% (Fig. 5) . Interestingly, a significant proportion of these selected 901 compounds were known iNOS inhibitors from previous programs and included close analogs of compound 3 that were in the astrazeneca compound collection. These compounds had been characterized previously and were known to compete with arginine in the active site of the fully formed dimer, and so these compounds were excluded from further tests, leaving 238 previously unidentified potential iNOS dimer binding compounds to go through to 10-point IC 50 determination in the InteraX and cytotoxicity assays.
The data from these determinations are summarized in Figure 7 . as expected, most of these compounds were not found to be active in the cytotoxicity assay; any toxicity of these compounds would naturally lead to a reduction in the readout of the InteraX assay, whereas all these compounds demonstrated an increase in β-galactosidase activity. The compounds that had a cytotoxicity/InteraX potency ratio <10 were taken forward for further profiling as iNOS inhibitors.
DISCUSSION
In an attempt to identify iNOS inhibitors that did not compete with arginine at the active site, we used the InteraX system to generate a robust cellular screen measuring iNOS dimerization. The InteraX system has previously been used to identify inhibitors of other protein-protein interactions that had a membrane-bound component (e.g., epidermal growth factor receptor [EgFr] and g-protein-coupled receptors [gPCrs]), where a high degree of protein folding and processing of the proteins within the cell were required. 9,10 These assays were apparently more complicated than a simple, soluble, dimeric enzyme such as iNOS, about which there is a wealth of published information on expression, structure, and activity. The human iNOS oxygenase domain, known to express as a soluble protein in Escherichia coli, 15 was used as the starting point for fusions 
Activators of InteraX assay
Inhibitors of InteraX assay
with the β-galactosidase mutants. The mouse C2C12 cell line used here is capable of expressing endogenous iNOS after induction with a mixture of cytokines 18 and so has all the necessary cellular machinery to make heme and tetrahydrobiopterin, which are needed for making active iNOS. The InteraX assay system uses 4 individual expression vectors, allowing formation of a fusion of each β-galactosidase mutant protein (∆α and ∆ω) with the N-terminus and C-terminus of the target protein. all 4 vectors containing the human iNOS oxygenase domain were tested in the appropriate combinations. Only 2 combinations gave significant β-galactosidase activity above baseline (Fig. 2a). Figure 2b is a model to represent these data and shows that for activity, 1 β-galactosidase-iNOS chimera of the dimeric combination needs to have the β-galactosidase protein fused to the N-terminus of the iNOS domain, and the other must be an iNOS-βgalactosidase chimera with the β-galactosidase mutant fused to the C-terminus of iNOS. The published structure of the crystallized dimeric iNOS oxygenase domain shows that the N-terminus from one monomer and the C-terminus from the opposite monomer lie on the same surface 15 and are separated by a distance of ~38 Å. β-galactosidase is active as a tetramer, and the crystal structure 19 shows that the N-terminus of one monomer is located extremely close (3 Å) to the C-terminus of an adjacent monomer. Therefore, for steric reasons, activity can only be seen with the pIX6-iNOS/pIX9-iNOS and pIX3-iNOS/pIX12-iNOS combinations, and of these, the pIX6-iNOS/pIX9-iNOS combination gave the highest β-galactosidase activity, probably arising from more optimal alignment of the complementing β-galactosidase mutants due to their associated linker peptides.
The correct combination of chimeric iNOS-β-galactosidase fusion proteins in the C2C12 cells gave sufficient constitutive β-galactosidase activity for a robust window after 24 h using 10,000 cells per well (as recommended by applied Biosystems). Only very minor assay development was required after the initial setup to optimize the use of robots to process 200 plates per day. Overall, the assay gave a robust signal-to-background ratio of 10-fold and an average z′ factor of 0.659.
The most surprising characteristic of the assay was its capacity to identify compounds that produce an increase in β-galactosidase activity as well as those that gave inhibition. This serendipitous finding allowed us to screen for 2 types of iNOS inhibitor using the same assay with only slight modifications.
Our Schild analysis of the InteraX assay with previously characterized iNOS dimerization and arginine-competitive iNOS inhibitors suggests that both types of compounds bind competitively at a common site on the iNOS monomer ( Fig. 8) . Compound 2 binds and prevents folding and dimerization of the iNOS monomers, causing a decrease in cellular β-galactosidase activity. In contrast, compound 3 can bind to the iNOS monomer, promoting dimerization, which is seen in the assay as an increase in β-galactosidase activity. Compound 1 has been co-crystallized with iNOS, and the resulting structure 20 shows that the imidazole coordinates with the iron atom of the heme in the iNOS monomer. There are structural similarities in the active site of iNOS monomers and dimers, 21 including the presence and location of heme. Structural studies show that arginine, 21 compound 1, and compound 3 22 all bind in a similar space above the heme. In addition, compounds 2, 3, and 4 all displace compound 1 from the iNOS monomer in binding assays (data not shown). These data give substance to a common overlapping site in the partially folded hemecontaining iNOS monomer that both types of compounds bind. The apparent affinity (a 2 ) of compound 3 to this site in the monomer in the InteraX assay is 400 nm, and this corresponds with the measured IC 50 of 250 nm in the iNOS induction inhibition assay. however, the IC 50 of compound 3 for the active recombinant iNOS dimer is ~10-fold higher at 37 nm, 11 which suggests it binds with higher affinity to the dimer than the monomer.
arginine can promote iNOS monomer dimerization 3 and stabilization of iNOS dimers. 16, 17 Our model ( Fig. 8) suggests that cellular arginine at ~100 µm can also bind to iNOS monomers and promote their dimerization and stabilization. arginine binds to fully formed dimeric iNOS with an affinity of ~10 µm, but it does not displace compound 1 from iNOS monomers at a concentration of 100 µm (data not shown), suggesting that the affinity of arginine for iNOS monomers is weaker than 100 µm. The model in Figure 8 does not take into account the role of tetrahydrobiopterin, which is also known to aid iNOS monomer dimerization and promote dimer stabilization in addition to arginine. Our data with compounds 3 and 4 suggest that the dimerization of iNOS monomers in the InteraX assay promoted by cellular arginine and tetrahydrobiopterin is not optimal, and the addition of arginine-competitive compounds with higher affinity for the monomer gives enhanced dimerization and β-galactosidase activity. The iNOS InteraX assay was developed into an hTS format and used successfully to screen more than 800,000 compounds. This allowed us to identify 1360 potential dimerization inhibitors that are not overtly cytotoxic. The overall hit rate of this process was therefore ~0.17%, which seemed quite high considering small molecular weight compounds were being used to inhibit a protein-protein interaction. Either inhibition of iNOS dimerization is a process that is particularly amenable to interference by small molecular weight compounds, or some of the compound hits may not be binding iNOS directly and could be inhibiting iNOS-β-galactosidase expression or preventing cell division without being cytotoxic over 24 h. Subsequent profiling in separate iNOS assays has confirmed that many of the 1360 hit compounds are indeed iNOS dimerization inhibitors (data not shown).
The InteraX assay also allowed us to identify 182 compounds that appeared to promote iNOS dimerization and were structurally different from known iNOS inhibitors. as this is a cell-based assay, the active compounds must have properties that allow cellular access and may be reasonable starting points for hit optimization.
We conclude that the iNOS InteraX assay described here is a robust cell-based hTS. It has utility in identifying 2 types of iNOS inhibitor in the same primary screen and can also be used as a useful tool to understand the pharmacology of different types of iNOS inhibitor. The InteraX system is ideally suited for cell-based hTS assays, giving reproducible data, and has obvious utility for developing hTS-friendly assays for other protein-protein interactions.
